<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
🌱 來自: [[Huppert&rsquo;s Notes]]
 Heart Failure (HF) #🚧 施工中 Heart Failure (HF) • Etiology:
- Left-sided HF: Ischemic vs."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Heart Failure (HF)"><title>Heart Failure (HF)</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.aa8c081727de296f4eab0c29bb65f75f.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.4eb2d4533233a3401afa81e9da7edcfe.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Heart Failure (HF)</h1><p class=meta>最後更新於
Jan 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Heart%20Failure%20%28HF%29.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><blockquote class=info-callout><p></p><p>🌱 來自: <a class="internal-link broken">Huppert&rsquo;s Notes</a></p></blockquote><a href=#heart-failure-hf--施工中><h1 id=heart-failure-hf--施工中><span class=hanchor arialabel=Anchor># </span>Heart Failure (HF) #🚧 施工中</h1></a><a href=#heart-failure-hf><h3 id=heart-failure-hf><span class=hanchor arialabel=Anchor># </span>Heart Failure (HF)</h3></a><p>•   Etiology:</p><p>-   Left-sided HF: Ischemic vs. nonischemic (e.g., arrhythmia or tachycardia-mediated; valvular disease; hypertension; drugs/toxins [chemotherapy, alcohol, stimulants]; infiltrative diseases [sarcoid, amyloid, hemochromatosis])</p><p>-   Right-sided HF: Most often due to L-sided heart failure. Other causes: cor pulmonale (e.g., due to OSA, COPD, pulmonary arterial hypertension)</p><p>•   Symptoms: Dyspnea, decreased exercise capacity, orthopnea, PND, nocturnal cough, fatigue, edema, abdominal bloating, early satiety</p><p>•   Physical exam:</p><p>-   Signs of congestion: S3, pulmonary crackles, Cheyne-Stokes respirations (deep/fast breathing cycling with apnea), jugular venous distention, hepatojugular reflex, hepatomegaly, pulsatile liver, lower extremity or sacral edema, IVC >2.1 cm and &lt;50% collapsible on POCUS, B-lines on lung POCUS (Table 1.11)</p><p><strong>TABLE 1.11 • Heart Failure: Signs of Congestion and Low Cardiac Output</strong></p><p>-   Signs of low cardiac output: Cool extremities, narrow pulse pressure, weak pulse, low SBP, altered mental status, reduced urine output (Table 1.11)</p><p>-   Other notable findings: Irregular rhythm, tachycardia, displaced point of maximal impulse (PMI), murmurs (e.g., MR, AS, TR), S4, reduced EF on POCUS</p><p>•   Classification:</p><p>-   American College of Cardiology (ACC)/American Heart Association (AHA) stages and New York Heart Association (NYHA) functional classes:</p><p><strong>•</strong>   <strong>A</strong> – At risk of HF but no diagnosis</p><p><strong>•</strong>   <strong>B</strong> – Structural heart disease but without symptoms of HF</p><p>-   NYHA I – No limitations on physical activity</p><p><strong>•</strong>   <strong>C</strong> – Structural heart disease with symptoms of HF</p><p>-   NYHA II – Slight limitation on physical activity, ordinary activity does not cause symptoms</p><p>-   NYHA III – Marked limitation on physical activity, ordinary activity causes symptoms</p><p><strong>•</strong>   <strong>D</strong> – Refractory HF requiring advanced therapies</p><p>-   NYHA IV – Symptoms at rest and inability to participate in physical activity</p><p>•   Diagnosis and work-up of heart failure:</p><p>-   TTE: Do when euvolemic</p><p><strong>•</strong>   EF &lt;40%: HF with reduced EF (HFrEF)</p><p><strong>•</strong>   EF >50% with diastolic dysfunction: HF with preserved EF (HFpEF)</p><p><strong>•</strong>   EF 40–50%: HF with mid-range EF (HFmrEF)</p><p>-   CXR: Kerley B-lines, pleural effusions, prominent interstitial markings and alveolar opacities (“butterfly” pattern)</p><p>-   Natriuretic peptides: Peptides released from the ventricles in response to stretch; elevated in acute and chronic HF but also increase with age, valvular disease, pulmonary hypertension, atrial arrhythmias (e.g., Afib), sepsis, CKD; false negative in obesity; useful to trend when patient’s baseline is known; has prognostic value in HF</p><p><strong>•</strong>   B-type natriuretic peptide (BNP): Uninterpretable in patients on sacubitril/valsartan (Entresto)</p><p>-   Can be used to exclude diagnosis of HF (<strong>“Breathing Not Properly” Study 2003</strong>)</p><p>•   &lt;20 pg/mL = Rule out HF in asymptomatic outpatient with 96% NPV</p><p>•   &lt;40 pg/mL = Rule out HF in symptomatic outpatient with 96% NPV</p><p>•   &lt;50 pg/mL = Rule out Acute Decompensated HF (ADHF) in ED patient with 96% NPV</p><p>•   &lt;100 pg/mL = Rule out ADHF in ED with 90% NPV</p><p>-   Can be used to identify HF:</p><p>•   >400 pg/mL = Identify ADHF in ED with 86% PPV</p><p><strong>•</strong>   NT-proBNP: Useful in patients on sacubitril/valsartan (Entresto), &lt;300 pg/mL useful to rule out ADHF in ED with 99% NPV (<strong>PRIDE study 2005</strong>)</p><p>-   ECG: Look for signs of the cause of HF such as LVH, atrial arrhythmias, tachycardia, Q waves, active ischemia, pacing spikes; low voltage ECG with LVH on ECHO suggests infiltrative disease</p><p>-   Troponin: Rule out active ischemia/ACS</p><p>-   Sodium: Hyponatremia may occur due to volume retention, diuretic use, increased neurohumoral activation; Na+ &lt;135 mEq/L associated with increased mortality in HF</p><p>-   Assess severity of advanced heart failure: BUN/Cr, LFTs, lactate</p><p>-   Assess for co-occurring conditions: HgA1c, lipid panel, TSH, iron studies</p><p>-   Assess heart failure etiology: Stress test or coronary angiogram (depending on pre-test probability of CAD), HIV, Utox, Upreg; sometimes: SPEP/SFLC, cardiac MRI, endomyocardial biopsy</p><p>•   Goals of hospitalization for ADHF:</p><p>-   Decongestion: IV diuretics (see Table 1.12; typically start by doubling the patient’s home diuretic dose, ensure urination within 30 min), BID electrolytes (repletion of K >4 mmol/L and Mg >2 mg/dL), strict I/Os (goal negative >2 L daily or more if tolerated), diurese fully to euvolemia (i.e., no JVD, no crackles, IVC&lt;2.1 cm and >50% collapsible), establish dry weight, trial on PO diuretics prior to discharge</p><p><strong>TABLE 1.12 • Diuretics</strong></p><p>-   Define and reverse triggers: <strong>FAILURES</strong> mnemonic</p><p><strong>•</strong>   <strong>F</strong>orgetting (i.e., not taking heart failure medications)</p><p><strong>•</strong>   <strong>A</strong>rrhythmia (especially Afib)</p><p><strong>•</strong>   <strong>I</strong>schemia</p><p><strong>•</strong>   <strong>L</strong>ifestyle (e.g., fluids, alcohol, salt, drugs)</p><p><strong>•</strong>   <strong>U</strong>p-regulation (e.g., in pregnancy, hyperthyroidism)</p><p><strong>•</strong>   <strong>R</strong>enal failure</p><p><strong>•</strong>   <strong>E</strong>mbolism</p><p><strong>•</strong>   <strong>S</strong>tenosis (e.g., aortic stenosis, renal artery stenosis)</p><p>-   Establish HF etiology: Reassess the reason that the patient has HF, determine if additional workup is required to define the etiology</p><p>-   Initiate and up-titrate guideline-directed medical therapy (GDMT): Prior to discharge, try to get patients on the maximum tolerated ACEi/ARB/ARNI, BB, MRA, SGLT2 inhibitor as indicated (see later)</p><p>-   Prevent rehospitalization: Schedule outpatient follow-up within 2 weeks to reassess volume exam, weight, labs, and medication tolerance</p><p>-   Additional measures for severe ADHF:</p><p><strong>•</strong>   Noninvasive ventilation (NIV): Respiratory support for cardiogenic pulmonary edema (CPAP preferred, may trial bilevel NIV if hypercapnia present)</p><p><strong>•</strong>   Inotropes: Dobutamine or milrinone</p><p><strong>•</strong>   Pulmonary artery catheter (Swann-Ganz catheter): Continuously measures cardiac and pulmonary pressures and can calculate cardiac output; has not been shown to improve outcomes in ADHF (<strong>ESCAPE 2005</strong>), but has a role in some patients, particularly those with cardiogenic shock, mixed shock, RV failure due to pulmonary hypertension, or those with a challenging clinical assessment</p><p>-   Treatment: Depends on the type of heart failure, as described below</p><a href=#hfref-ef-40-heart-failure-with-reduced-ejection-fraction><h5 id=hfref-ef-40-heart-failure-with-reduced-ejection-fraction><span class=hanchor arialabel=Anchor># </span>HFrEF (EF &lt;40%): Heart failure with reduced ejection fraction</h5></a><p>•   Lifestyle: Sodium restriction (&lt;4 g/day), weight loss, smoking cessation, restrict alcohol, daily weights</p><p>•   Symptomatic relief: Diuretics. Common recommendation for patients: If weight increases 3–5 lb, double diuretic and K+ repletion and call provider.</p><p>•   Guideline-directed medical therapy for HFrEF: Medications with mortality benefit</p><p>-   <strong>ACE inhibitor (ACEi)</strong> (<strong>SAVE 1992, SOLVD 1991</strong>)</p><p><strong>•</strong>   ~20% mortality reduction</p><p><strong>•</strong>   Recommended for EF &lt;40%, NYHA I-IV</p><p><strong>•</strong>   Medications: Lisinopril (initial = 2.5–5 mg qD; goal = 40 mg qD). Alternatively, can use short-acting captopril (initial = 6.25 mg TID; goal = 50 mg TID) for easier titration inpatient then convert to once-daily lisinopril prior to discharge. Ratio captopril:lisinopril is 5:1 (captopril 50 mg TID = lisinopril 30 mg qD). Other options: benazepril, enalapril, ramipril</p><p><strong>•</strong>   Side effects: Hypotension, hyperkalemia, cough; careful in CKD, bilateral renal artery stenosis. Teratogen</p><p>-   <strong>Angiotensin receptor blockers (ARBs)</strong> (<strong>Val-HeFT 2001; HEAAL 2009</strong>)</p><p><strong>•</strong>   ~15% mortality reduction</p><p><strong>•</strong>   Recommended for EF &lt;40%, NYHA II–IV</p><p><strong>•</strong>   Medications: Losartan (initial = 12.5–25 mg; goal = 50 mg daily). Alternative for patients who do not tolerate ACEi (usually due to cough). Other options: valsartan, candesartan</p><p><strong>•</strong>   Side effects: Hypotension, hyperkalemia. Cough less common with ARBs than ACEi, but can occur. Teratogen</p><p>-   <strong>Angiotensin receptor neprilysin inhibitor (ARNI) + ARB (sacubitril/valsartan [Entresto]) (PARADIGM-HF 2014)</strong></p><p><strong>•</strong>   Up tô15% mortality reduction (over ACEi)</p><p><strong>•</strong>   Recommended for EF ≤35% and BNP ≥150 pg/mL <em><strong>or</strong></em> NT-proBNP ≥600 pg/mL <em><strong>or</strong></em> hospitalization</p><p><strong>•</strong>   Medications: Sacubitril/valsartan (initial = 24/26 mg BID; goal = 97/103 mg BID)</p><p><strong>•</strong>   Side effects: Hyperkalemia, angioedema. Do not combine with ACEi due to risk of angioedema</p><p>-   <strong>Beta blockers</strong> (<strong>MERIT-HF 1999</strong>)</p><p><strong>•</strong>   ~35% mortality reduction</p><p><strong>•</strong>   Recommended for EF &lt;40%, NYHA I–IV</p><p><strong>•</strong>   Medications: Carvedilol if hypertensive (initial 3.125 mg BID; goal = 25 mg BID) or metoprolol succinate if normotensive (initial = 12.5–25 mg qD; goal = 200 mg qD). When up-titrating can start with metoprolol tartrate q6h and then convert total daily dose 1:1 to metoprolol succinate at discharge</p><p><strong>•</strong>   Side effects: Hypotension, bradycardia</p><p><strong>•</strong>   Note: OK to continue home BB in stable patient with ADHF but do not start new BB until nearing euvolemia</p><p>-   <strong>Mineralocorticoid receptor antagonists (MRAs)</strong> (<strong>RALES 1999, EMPHASIS-HF 2011</strong>)</p><p><strong>•</strong>   ~30% mortality reduction</p><p><strong>•</strong>   Recommended for EF ≤35%, NYHA II–IV</p><p><strong>•</strong>   Medications: Spironolactone (initial 12.5–25 mg qD; goal = 50 mg qD) or eplerenone (initial 25 mg qD; goal 50 mg qD, less gynecomastia)</p><p><strong>•</strong>   Side effects: Hyperkalemia. Do not use in CKD (Cr >2.5)</p><p>-   <strong>SGLT2 inhibitors</strong> (<strong>DAPA-HF 2019</strong>)</p><p><strong>•</strong>   ~20% mortality reduction (over standard guideline-directed medical therapy [GDMT])</p><p><strong>•</strong>   Recommended for EF ≤40%, especially in patients with diabetes</p><p><strong>•</strong>   Medications: Dapagliflozin, canagliflozin, empagliflozin</p><p>•   Less frequently used:</p><p>-   <strong>Hydralazine-isosorbide dinitrate</strong> (<strong>A = HeFT 2004</strong>)</p><p><strong>•</strong>   Mortality reduction in persons who self-identified as Black (defined as of African descent). Beneficial if hypertensive and/or symptomatic despite GDMT, especially in African American patients</p><p><strong>•</strong>   Medications: Hydralazine 37.5–75 mg/Isordil 20–40 mg TID</p><p>-   <strong>Ivabradine (SHIFT 2010)</strong></p><p><strong>•</strong>   No mortality reduction</p><p><strong>•</strong>   SA node (funny current) blocker. Consider if HR&lt;70 bpm after on maximum dose beta blocker</p><p>-   <strong>Tolvaptan</strong></p><p><strong>•</strong>   No mortality reduction</p><p><strong>•</strong>   Consider if severe hyponatremia (e.g., Na+ &lt;120 mEq/L) despite fluid restriction. Initiated inpatient only with close sodium monitoring.</p><p><strong>•</strong>   Do not use for >30 days. Do not use in liver disease.</p><p>-   <strong>Digoxin</strong></p><p><strong>•</strong>   Unclear mortality benefit and potential for harm. Consider rarely if a patient is symptomatic despite GDMT.</p><p><strong>•</strong>   Dose 0.125 mg daily and maintain serum digoxin level &lt;1 ng/mL</p><p><strong>•</strong>   Side effects: Dizziness, diarrhea, rash, confusion</p><p>•   Procedures:</p><p>-   <strong>Implantable cardioverter defibrillator (ICD):</strong> Consider if EF &lt;35% after 3–6 months on medical therapy, for prevention of sudden cardiac death.</p><p>-   <strong>Cardiac resynchronization therapy (CRT):</strong> Cardiac resynchronization (placement of a pacemaker with RV and LV leads to synchronize RV/LV contraction). Consider if EF &lt;35%, NYHA II–IV, wide QRS (at least >120 ms; particularly with LBBB) after optimal medical therapy for 3–6 months.</p><p>-   <strong>CardioMEMS:</strong> Implantable device that monitors changes in pulmonary artery pressure to allow clinicians to remotely titrate diuretics. Consider in patients with frequent hospitalizations, difficult to manage volume status.</p><p>•   Advanced therapies: Consider in ACC/AHA Stage D/NYHA IV despite guideline-directed medical therapy:</p><p>-   <strong>LVAD (Left Ventricular Assist Device):</strong> For bridge to transplant or destination therapy</p><p>-   <strong>Heart transplant</strong></p><p>-   <strong>IV inotropic therapy:</strong> For symptom benefit/quality of life often as a bridge to transplant</p><p>-   <strong>Palliative care:</strong> For symptom benefit/quality of life</p><a href=#hfmref-ef-4050-heart-failure-with-mid-range-ejection-fraction><h5 id=hfmref-ef-4050-heart-failure-with-mid-range-ejection-fraction><span class=hanchor arialabel=Anchor># </span>HFmrEF (EF 40–50%): Heart failure with mid-range ejection fraction</h5></a><p>•   Definition: Between HFrEF and HFpEF. Recognized by most as a subcategory of HFreF</p><p>•   Treatment: Unclear how exactly to manage given limited clinical trials directed at this population, but generally treated like HFrEF</p><a href=#hfrecef-ef--40-that-improves-to--50-heart-failure-with-recovered-ejection-fraction><h5 id=hfrecef-ef--40-that-improves-to--50-heart-failure-with-recovered-ejection-fraction><span class=hanchor arialabel=Anchor># </span>HFrecEF (EF &lt; 40% that improves to > 50%): Heart failure with recovered ejection fraction</h5></a><p>•   Definition: HFrEF that recovers over time with treatment</p><p>•   Treatment: Unclear exactly how to manage but should NOT stop HFrEF therapies</p><a href=#hfpef-ef--50--clinical-symptoms-of-hf-heart-failure-with-preserved-ejection-fraction><h5 id=hfpef-ef--50--clinical-symptoms-of-hf-heart-failure-with-preserved-ejection-fraction><span class=hanchor arialabel=Anchor># </span>HFpEF (EF > 50% + clinical symptoms of HF): Heart failure with preserved ejection fraction</h5></a><p>•   Treatment: Data less clear; unclear if standard HFrEF medications help this population, but trials have largely not shown benefit</p><p>•   Mainstays of treatment:</p><p>-   Management of hypertension</p><p>-   Diuretics, lifestyle changes, consideration of remote hemodynamic monitoring (e.g., CardioMEMs) when difficult to control - MRAs: Spironolactone decreases hospitalizations (<strong>TOPCAT 2014</strong>; controversial study due to differences in subgroup analysis by region)</p><p>-   SGLT-2 inhibitors may have benefit (trials on-going)</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/Cardiology-diseases-and-pathophysiology/ data-ctx="Heart Failure (HF)" data-src=/Cardiology-diseases-and-pathophysiology class=internal-link>Cardiology diseases and pathophysiology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>